<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390403</url>
  </required_header>
  <id_info>
    <org_study_id>NABTT-0602 CDR0000507451</org_study_id>
    <secondary_id>U01CA062475</secondary_id>
    <secondary_id>NABTT-0602</secondary_id>
    <nct_id>NCT00390403</nct_id>
  </id_info>
  <brief_title>Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <official_title>A Phase I, Open Label Study of AT-101 Plus Radiotherapy and Temozolomide and of AT-101 Plus Adjuvant Temozolomide for Patients With Newly-Diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gossypol and temozolomide, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Gossypol may help&#xD;
      temozolomide work better by making tumor cells more sensitive to the drug. Gossypol may also&#xD;
      make tumor cells more sensitive to radiation therapy. Giving gossypol and temozolomide&#xD;
      together with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of gossypol when given&#xD;
      together with temozolomide with or without radiation therapy in treating patients with newly&#xD;
      diagnosed glioblastoma multiforme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of gossypol (AT-101) when administered with&#xD;
           radiotherapy (RT) and concurrent temozolomide (TMZ) in patients with newly diagnosed&#xD;
           glioblastoma multiforme.&#xD;
&#xD;
        -  Determine the MTD of gossypol when administered with adjuvant TMZ after standard RT and&#xD;
           concurrent TMZ in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Assess the toxicity of these treatment regimens.&#xD;
&#xD;
        -  Assess and describe the pharmacokinetics of gossypol.&#xD;
&#xD;
        -  Determine, preliminarily, the therapeutic activities of these regimens.&#xD;
&#xD;
        -  Determine the relationship between these regimens and cellular and molecular features&#xD;
           identified in tumor biopsy specimens.&#xD;
&#xD;
      OUTLINE: This is a multicenter, open-label, nonrandomized, dose-escalation study of gossypol.&#xD;
      Patients are assigned to 1 of 2 treatment groups. Patients who participate in group I are NOT&#xD;
      eligible for group II.&#xD;
&#xD;
        -  Group I: Patients receive oral gossypol and undergo radiotherapy once daily 5 days a&#xD;
           week for up to 6 weeks. Patients also receive oral temozolomide once daily for up to 6&#xD;
           weeks. Treatment continues in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
        -  Group II: Patients receive oral temozolomide on days 1-5 and oral gossypol once daily on&#xD;
           days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-10 patients per treatment group receive escalating doses of gossypol until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 or&#xD;
      3 of 10 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients undergo blood collection periodically for pharmacokinetic studies. Tumor tissue&#xD;
      samples are examined for biomarkers including, but not limited to, Bcl-2 family protein&#xD;
      expression (e.g., Bcl-2, Bcl-xL, MCl-1, Bax, Bak, and BH3 domain), MGMT gene methylation&#xD;
      status, and gene expression array.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of gossypol</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic activity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular and molecular outcomes (intratumoral expression levels of biomarkers, including Bcl-2 family protein expression [e.g., Bcl-2, Bcl-xL, MCl-1, Bax, Bak, BH3 domain], MGMT gene methylation status, and gene expression array)</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-(-)-gossypol acetic acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme)&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Completed surgery within the past 6 weeks (group I)&#xD;
&#xD;
               -  Received radiotherapy and concomitant temozolomide at least 4 weeks but no more&#xD;
                  than 7 weeks prior to start of study treatment (group II)&#xD;
&#xD;
          -  Must be on a stable corticosteroid regimen (no increase for 5 days)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Creatinine ≤1.5 mg/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Mini Mental State Exam score ≥ 15&#xD;
&#xD;
          -  Must be able to swallow and retain oral medication&#xD;
&#xD;
          -  No serious concurrent infection or medical illness that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No other malignancy within the past 5 years, except for curatively treated carcinoma&#xD;
             in situ or basal cell carcinoma of the skin&#xD;
&#xD;
          -  No sensory neuropathy ≥ grade 2&#xD;
&#xD;
          -  No allergies to gossypol&#xD;
&#xD;
          -  No symptomatic hypercalcemia or hypercalcemia &gt; grade 2&#xD;
&#xD;
          -  No gastrointestinal disease including any of the following:&#xD;
&#xD;
               -  Malabsorption syndrome&#xD;
&#xD;
               -  Disease significantly affecting gastrointestinal function&#xD;
&#xD;
               -  Ulcerative colitis&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Partial or complete small bowel obstruction&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from the immediate postoperative period&#xD;
&#xD;
          -  No prior radiotherapy, chemotherapy, immunotherapy, therapy with biologic agents&#xD;
             (including immunotoxins, immunoconjugates, antisense agents, peptide-receptor&#xD;
             antagonists, interferons, interleukins, tumor-infiltrating lymphocyte therapy,&#xD;
             lymphokine-activated killer cells or gene therapy), or hormonal therapy for this brain&#xD;
             tumor (group I)&#xD;
&#xD;
               -  Prior glucocorticoid therapy allowed&#xD;
&#xD;
          -  No prior polifeprosan 20 with carmustine implant (Gliadel wafers) (group I)&#xD;
&#xD;
          -  No prior gossypol&#xD;
&#xD;
          -  No prior radiosurgery or brachytherapy&#xD;
&#xD;
          -  No prior resection of the stomach or small intestine&#xD;
&#xD;
          -  No other concurrent anticancer therapy (i.e., chemotherapeutics or investigational&#xD;
             agents)&#xD;
&#xD;
          -  No concurrent cytochrome p450 enzyme-inducing anticonvulsant drugs&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF)&#xD;
&#xD;
          -  No concurrent iron supplements&#xD;
&#xD;
               -  Nutritional supplements containing iron allowed&#xD;
&#xD;
          -  No concurrent intensity-modulated radiotherapy&#xD;
&#xD;
          -  No concurrent electron, particle, implant, or stereotactic radiosurgery boost&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Fiveash, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute at University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>October 18, 2006</study_first_submitted>
  <study_first_submitted_qc>October 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2006</study_first_posted>
  <last_update_submitted>May 1, 2012</last_update_submitted>
  <last_update_submitted_qc>May 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetic Acid</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Retinol acetate</mesh_term>
    <mesh_term>Gossypol acetic acid</mesh_term>
    <mesh_term>Gossypol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

